Braftovi

Showing 2 posts of 2 posts found.

Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype

May 22, 2019
Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma

Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …

imp_pologne2

NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma

January 21, 2019
Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …

Latest content